Envestnet Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$68.5M Buy
109,838
+686
+0.6% +$467K 0.02% 729
2026
Q1
$84.3M Buy
109,152
+20,180
+23% +$15.4M 0.02% 590
2025
Q4
$68.7M Sell
88,972
-12,589
-12% -$8.55M 0.02% 607
2025
Q3
$57.1M Sell
101,561
-1,861
-2% -$1.05M 0.02% 718
2025
Q2
$54.3M Sell
103,422
-13,305
-11% -$7.43M 0.02% 715
2025
Q1
$74M Buy
116,727
+25,589
+28% +$17.6M 0.02% 562
2024
Q4
$64.9M Buy
91,138
+10,060
+12% +$8.44M 0.02% 600
2024
Q3
$85.2M Buy
81,078
+5,626
+7% +$6.26M 0.03% 524
2024
Q2
$79.3M Buy
75,452
+8,209
+12% +$7.96M 0.03% 507
2024
Q1
$64.7M Buy
67,243
+3,760
+6% +$3.58M 0.02% 569
2023
Q4
$55.8M Buy
63,483
+5,794
+10% +$4.77M 0.02% 573
2023
Q3
$47.5M Sell
57,689
-5,133
-8% -$4.03M 0.02% 595
2023
Q2
$45.1M Sell
62,822
-1,853,952
-97% -$1.43B 0.02% 567
2023
Q1
$50.5M Buy
1,916,774
+1,848,784
+2,719% +$1.39B 0.02% 501
2022
Q4
$49.1M Sell
67,990
-10,152
-13% -$7.49M 0.03% 487
2022
Q3
$53.8M Buy
78,142
+3,415
+5% +$2.15M 0.03% 419
2022
Q2
$44.2M Sell
74,727
-5,003
-6% -$3.25M 0.02% 476
2022
Q1
$55.7M Sell
79,730
-8,693
-10% -$5.5M 0.03% 451
2021
Q4
$55.8M Buy
88,423
+20,763
+31% +$12.8M 0.03% 456
2021
Q3
$40.9M Buy
67,660
+2,908
+4% +$1.81M 0.02% 527
2021
Q2
$36.2M Sell
64,752
-10
-0% -$5.07K 0.02% 559
2021
Q1
$30.6M Buy
64,762
+3,335
+5% +$1.62M 0.02% 566
2020
Q4
$29.7M Sell
61,427
-561
-0.9% -$303K 0.02% 500
2020
Q3
$34.7M Sell
61,988
-227
-0.4% -$138K 0.03% 397
2020
Q2
$38.8M Buy
62,215
+6,278
+11% +$3.56M 0.04% 339
2020
Q1
$27.3M Buy
55,937
+11,309
+25% +$4.66M 0.03% 365
2019
Q4
$16.8M Sell
44,628
-442
-1% -$149K 0.02% 587
2019
Q3
$12.5M Sell
45,070
-756
-2% -$224K 0.01% 657
2019
Q2
$14.3M Sell
45,826
-3,701
-7% -$1.23M 0.02% 585
2019
Q1
$20.3M Sell
49,527
-6,188
-11% -$2.55M 0.03% 445
2018
Q4
$20.8M Buy
55,715
+54,624
+5,007% +$20M 0.03% 352
2018
Q3
$441K Sell
1,091
-14,216
-93% -$5.41M ﹤0.01% 946
2018
Q2
$5.28M Sell
15,307
-284
-2% -$88.8K 0.01% 480
2018
Q1
$5.32M Sell
15,591
-7,264
-32% -$2.53M 0.02% 379
2017
Q4
$8.59M Sell
22,855
-556
-2% -$225K 0.02% 429
2017
Q3
$10.5M Buy
23,411
+95
+0.4% +$45.2K 0.03% 364
2017
Q2
$11.4M Buy
23,316
+2,078
+10% +$909K 0.03% 337
2017
Q1
$8.23M Buy
21,238
+5,264
+33% +$1.95M 0.03% 408
2016
Q4
$5.86M Buy
15,974
+2,095
+15% +$797K 0.02% 489
2016
Q3
$5.58M Sell
13,879
-2,925
-17% -$1.17M 0.02% 542
2016
Q2
$5.87M Sell
16,804
-551
-3% -$212K 0.02% 562
2016
Q1
$6.25M Buy
17,355
+1,245
+8% +$513K 0.03% 508
2015
Q4
$8.75M Buy
16,110
+1,307
+9% +$708K 0.04% 393
2015
Q3
$6.88M Sell
14,803
-1,975
-12% -$1.06M 0.03% 439
2015
Q2
$8.56M Sell
16,778
-741
-4% -$362K 0.04% 422
2015
Q1
$7.91M Buy
17,519
+16,106
+1,140% +$6.83M 0.04% 428
2014
Q4
$580K Sell
1,413
-31
-2% -$12.2K 0.01% 678
2014
Q3
$521K Buy
1,444
+13
+0.9% +$4.36K 0.01% 773
2014
Q2
$404K Buy
1,431
+47
+3% +$13.9K ﹤0.01% 820
2014
Q1
$416K Buy
1,384
+332
+32% +$102K ﹤0.01% 700
2013
Q4
$290K Buy
1,052
+230
+28% +$66.2K ﹤0.01% 742
2013
Q3
$257K Buy
822
+58
+8% +$15.3K ﹤0.01% 743
2013
Q2
$172K Buy
+764
New +$178K ﹤0.01% 826

Other funds holding REGN

Envestnet Asset Management's REGN Position: Q2 2026 in Review

Envestnet Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.63% in Q2 2026, buying an estimated $467K and bringing the position to 109,838 shares worth $68.5M. The position accounts for 0.02% of the portfolio, ranked #729.

Envestnet Asset Management first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $85.2M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Envestnet Asset Management held 109,838 shares of Regeneron Pharmaceuticals worth $68.5M as of Q2 2026.
  • Envestnet Asset Management bought 686 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $467K.
  • Regeneron Pharmaceuticals made up 0.02% of Envestnet Asset Management's portfolio in Q2 2026, its #729 holding.
  • Envestnet Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Envestnet Asset Management's Regeneron Pharmaceuticals position peaked at $85.2M in Q3 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.